Companies › Paradigm Therapeutics
1 active drug program in 1 registered trial: 1 Phase 3; Other; next expected readout May 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| SD-101 Dermal Cream (6%) Allantoin, a diureide glyoxylic acid derivative promoting wound healing and skin barrier f | – | Phase 3 | Epidermolysis Bullosa (EB) | May 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07482787 | SD-101 Dermal Cream (6%) | Phase 3 | Epidermolysis Bullosa (EB) | Other | May 2027 |
No annotated target.
–
Huons Biopharma Neuren Pharmaceuticals Tetra Discovery Partners Prove pharm Neuraptive Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.